| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0002-9343(90)90345-E |
| P8608 | Fatcat ID | release_5thzbxp5c5hu3ibg6dogjjqy3y |
| P698 | PubMed publication ID | 2393036 |
| P2093 | author name string | Wallace DJ | |
| Kern PA | |||
| Metzger AL | |||
| Stecher VJ | |||
| Turnbull BA | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hydroxychloroquine | Q421094 |
| lipid | Q11367 | ||
| rheumatism | Q684924 | ||
| P304 | page(s) | 322-326 | |
| P577 | publication date | 1990-09-01 | |
| P1433 | published in | American Journal of Medicine | Q2842959 |
| P1476 | title | Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids | |
| P478 | volume | 89 |
| Q36290168 | 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus |
| Q34389286 | A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role |
| Q33915419 | Accelerated atheroma in lupus--background |
| Q37658524 | Accelerated atherosclerosis in SLE: mechanisms and prevention approaches |
| Q34601733 | Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? |
| Q50146708 | Adherence with advice and prescriptions in SLE is mostly good, but better follow up is needed: a study with a questionnaire. |
| Q47625953 | An overview of the treatment of childhood SLE. |
| Q39178961 | An update on diet and nutritional factors in systemic lupus erythematosus management. |
| Q34226976 | Antimalarial therapy: a panacea for mild lupus? |
| Q34604474 | Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit |
| Q34297582 | Antimalarials--the 'real' advance in lupus |
| Q34129797 | Antimalarials. |
| Q51673816 | Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis? |
| Q41921823 | Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications |
| Q36283443 | Atherogenesis and autoimmune disease: the model of lupus |
| Q34108806 | Atherosclerosis and systemic lupus erythematosus |
| Q36421188 | Autoimmune thyroid disease in rheumatoid arthritis: a global perspective |
| Q51031046 | Biochemical characterization of ADP-ribose polymer metabolism in SLE. |
| Q88917533 | Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis |
| Q37808570 | Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications |
| Q41943173 | Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients |
| Q36443689 | Contemporary treatment of systemic lupus erythematosus: an update for clinicians. |
| Q41930670 | Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. |
| Q93250708 | Covid-19 treatment update: follow the scientific evidence |
| Q54218397 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. |
| Q33422958 | Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus |
| Q46490126 | Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL). |
| Q36573102 | Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study |
| Q35605663 | Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study |
| Q33633643 | Drugs to Treat Systemic Lupus Erythematosus: Relationship between Current Use and Cardiovascular Risk Factors |
| Q35547301 | Dyslipidemia and rheumatoid arthritis |
| Q36126483 | Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus |
| Q43417859 | Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. |
| Q37582574 | Epidemiology of atherosclerosis in systemic lupus erythematosus |
| Q41911999 | Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: A systematic review and meta-analysis |
| Q44367989 | Food restriction and fish oil suppress atherogenic risk factors in lupus-prone (NZB x NZW) F1 mice |
| Q53653844 | Glucocorticoid use is associated with increase in HDL and no change in other lipids in rheumatoid arthritis patients. |
| Q33915484 | How accelerated atherosclerosis in SLE has changed our management of the disorder |
| Q53609113 | Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. |
| Q41921127 | Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. |
| Q41925716 | Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma |
| Q38029146 | Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects |
| Q37854742 | Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy |
| Q41929433 | Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. |
| Q41933145 | Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients |
| Q41953362 | Hydroxychloroquine: a diabetic drug in disguise? |
| Q37827403 | Hydroxychloroquine: from malaria to autoimmunity |
| Q46643929 | Hydroxychloroquine: the cornerstone of lupus therapy |
| Q64227620 | Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis |
| Q30791606 | Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort |
| Q35840758 | Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study |
| Q43637712 | Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients |
| Q39608521 | Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome |
| Q26774815 | Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives |
| Q33722871 | Management of lipid disorders |
| Q43275139 | Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. |
| Q50861922 | Metabolic syndrome in Chinese patients with systemic lupus erythematosus: no association with plasma cortisol level. |
| Q46404846 | Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain |
| Q33425745 | Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients |
| Q34007922 | New concepts in antimalarial use and mode of action in dermatology |
| Q38026787 | New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. |
| Q41915915 | Polymorphism of the β3-adrenergic receptor and lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus treated with chloroquine |
| Q46144242 | Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus |
| Q33893354 | Premature atherosclerosis in systemic lupus erythematosus |
| Q77798512 | Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus |
| Q41917167 | Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort |
| Q44652580 | Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study |
| Q45125883 | Sequential evaluation of clinical and laboratory changes amongst children suffering from lupus nephritis during intermittent intravenous cyclophosphamide therapy. |
| Q38518891 | Serum oxidized low-density lipoproteins in rheumatoid arthritis |
| Q43419630 | Systemic lupus erythematosus and cardiovascular disease |
| Q34017775 | Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study |
| Q35637240 | Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study |
| Q40506580 | Systemic lupus erythematosus--disease management |
| Q49787347 | The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients |
| Q36577380 | The management of pediatric systemic lupus erythematosus |
| Q94672281 | The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? |
| Q45220920 | The prevalence of dyslipoproteinemia in Thai patients with systemic lupus erythematosus |
| Q36464352 | Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis |
| Q78814998 | Treatment of lupus nephritis |
| Q51104578 | Use of Hydroxychloroquine Is Associated With Improved Lipid Profile in Rheumatoid Arthritis Patients. |
| Q34027673 | Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study |
| Q84600129 | [Antimalarials: an update in rheumatic diseases] |
| Q84600749 | [Comorbidity of systemic lupus erythematosus] |
Search more.